publication venue for Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer 2023 Current Scenario of Clinical Cancer Research in Latin America and the Caribbean. 30:653-662. 2023
